DEM BioPharma Launches with $70 Million Financing
Company will pursue untapped opportunities in the field of innate immune system checkpoints to eliminate cancer Proprietary platform leverages CRISPR screening and macrophage biology to systematically discover and drug “don’t eat me” (DEM) and “eat me” (EM) signals CAMBRIDGE, Mass.–(BUSINESS WIRE)–DEM BioPharma, Inc. (DEM Bio), an immuno-oncology company developing therapies that target novel innate immune … [Read more…]
